Evaluation of the Service Provision of Cognitive Screening for Multiple Sclerosis in a discrete Jersey-based population.
This study aimed to develop a more coordinated and comprehensive assessment pathway and assessment framework for Multiple Sclerosis (MS) patients in a specialist nurse-led service selected for Natalizumab infusions. Follow-up assessments provided were often on the basis of patients’ self-reported difficulties. However, depressed patients are likely to over-report cognitive deficits, whilst patients with metamemory deficits may underestimate their cognitive abilities. A purposive sample (N=51) of MS patients was selected for Natalizumab (14 male, 37 were female; Mean age= 43.2,SD: 9.27). We collected the outcomes of cognitive screening received at baseline and at follow up. The data was summarised and analysed with appropriate database and statistical packages. Descriptive statistics revealed that 71% (n=36) of the samplewere not within the age range for the normative data of ACE-III. Of the overall sample, only 31% (n = 16) had received acognitive screening follow up. In order to improve the Service Provision of cognitive screening in patients with MS, as well as relevant processes and quality of data, a number of areas for improvement have been identified